Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Study In Circulation Questions Cost Effectiveness Of VADs

This article was originally published in The Gray Sheet

Executive Summary

A recent analysis of the cost effectiveness of ventricular assist devices used as destination therapy for heart failure suggests room for improvement.

You may also be interested in...

Destination Therapy HeartMate II Implants Drives Thoratec’s Fast Growth

“Looking forward, we anticipate that the DT indication will continue to drive growth across the spectrum of centers, but with an increasingly important contribution from smaller transplant and open heart centers,” CEO Gerhard Burbach said.

Reimbursement In Brief

CMS opens national coverage analysis on VADs, proposes regulatory reform and announces new ESRD initiative. More reimbursement news.

Thoratec Takes Over REVIVE-IT LVAD Trial From HeartWare

The pilot trial, cosponsored by NIH, will give ventricular assist devices a chance to prove their worth in heart failure patients not yet in the final stage of their illness.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts